Wednesday, January 22, 2020 12:02:24 AM
MNTA will be the exception. They'll move on to be a powerhouse just watch.
They already have $545 Million so there's no need for them to do a secondary in the near future. Unlike the many small biotech that you mention who fail because they have one or two drug pipelines that they inlicense, Momenta has several that they create out of their labs. M281, M254, M230, CD38 SIFbody, Glatopa, EYlea and much more to come... And although they haven't mentioned partnership it will come, as sure as the SUN rises from the West.
By the way do you think there's a pathway for a breakthrough therapy on M254? That Chinese bug is gonna go global and knowing that IVIG boosts the immune system they'll be looking for a substitute.
How about CD38 SIFbody? Did you see that cell depletion graph? That is very impressive. I can see the FDA looking into it. Definitely a breakthrough therapy is in the cards for this molecule.
Yep IAN. If I were you I'd look for an entry into MNTA. Sitting on the fence gets pretty boring don't you think?
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM